Literature DB >> 8094590

Minimal efficacy requirements for malarial vaccines to significantly lower transmission in epidemic or seasonal malaria.

A Saul1.   

Abstract

The effect of vaccines against the pre-erythrocytic, the erythrocytic and the sexual stages of malaria on the transmission of malaria was examined using a simulation model of seasonal or epidemic transmission. The primary outcome of the model was the number of cases of malaria present at the end of the transmission season. A range of efficacy for the vaccine, or of coverage of the population and of vectorial capacities were tested for each vaccine type. For a similar level of efficacy or coverage under conditions simulating hypo or mesoendemic malaria, all types of vaccines gave similar decreases in the number of people infected. Although all vaccine types gave significant reductions in malaria incidence at efficacy or coverage levels considerably lower than that required to completely block transmission, this reduction in case numbers was highly dependent on the vectorial capacity. The simulation model is equally applicable to other transmission blocking measures such as insecticide treated bed nets.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8094590     DOI: 10.1016/0001-706x(93)90013-2

Source DB:  PubMed          Journal:  Acta Trop        ISSN: 0001-706X            Impact factor:   3.112


  10 in total

1.  The potential impact of integrated malaria transmission control on entomologic inoculation rate in highly endemic areas.

Authors:  G F Killeen; F E McKenzie; B D Foy; C Schieffelin; P F Billingsley; J C Beier
Journal:  Am J Trop Med Hyg       Date:  2000-05       Impact factor: 2.345

Review 2.  Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination.

Authors:  Teun Bousema; Chris Drakeley
Journal:  Clin Microbiol Rev       Date:  2011-04       Impact factor: 26.132

3.  A simplified model for predicting malaria entomologic inoculation rates based on entomologic and parasitologic parameters relevant to control.

Authors:  G F Killeen; F E McKenzie; B D Foy; C Schieffelin; P F Billingsley; J C Beier
Journal:  Am J Trop Med Hyg       Date:  2000-05       Impact factor: 2.345

4.  Transmission-blocking interventions eliminate malaria from laboratory populations.

Authors:  A M Blagborough; T S Churcher; L M Upton; A C Ghani; P W Gething; R E Sinden
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

5.  An agent-based model of dengue virus transmission shows how uncertainty about breakthrough infections influences vaccination impact projections.

Authors:  T Alex Perkins; Robert C Reiner; Guido España; Quirine A Ten Bosch; Amit Verma; Kelly A Liebman; Valerie A Paz-Soldan; John P Elder; Amy C Morrison; Steven T Stoddard; Uriel Kitron; Gonzalo M Vazquez-Prokopec; Thomas W Scott; David L Smith
Journal:  PLoS Comput Biol       Date:  2019-03-20       Impact factor: 4.475

6.  3'-RACE Amplification of Aminopeptidase N Gene from Anopheles stephensi Applicable in Transmission Blocking Vaccines.

Authors:  Hanieh Bokharaei; Abbasali Raz; Sedigheh Zakeri; Navid Dinparast Djadid
Journal:  Avicenna J Med Biotechnol       Date:  2012-07

7.  Advantages of larval control for African malaria vectors: low mobility and behavioural responsiveness of immature mosquito stages allow high effective coverage.

Authors:  Gerry F Killeen; Ulrike Fillinger; Bart G J Knols
Journal:  Malar J       Date:  2002-06-21       Impact factor: 2.979

8.  Zooprophylaxis or zoopotentiation: the outcome of introducing animals on vector transmission is highly dependent on the mosquito mortality while searching.

Authors:  Allan Saul
Journal:  Malar J       Date:  2003-09-19       Impact factor: 2.979

9.  A weather-driven model of malaria transmission.

Authors:  Moshe B Hoshen; Andrew P Morse
Journal:  Malar J       Date:  2004-09-06       Impact factor: 2.979

Review 10.  Malaria vaccine: a future hope to curtail the global malaria burden.

Authors:  Kaliyaperumal Karunamoorthi
Journal:  Int J Prev Med       Date:  2014-05
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.